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Effect of on-line conductivity plasma ultrafiltrate kinetic modeling on
cardiovascular stability of hemodialysis patients. The aim of this multi-
center, prospective, randomized cross-over study was to clarify whether
on-line conductivity ultrafiltrate kinetic modeling (treatment B), as a
substitute for sodium kinetic modeling, is capable of reducing intradialytic
cardiovascular instability in comparison with standard treatment (treat-
ment A), by reducing the sodium balance variability. Both treatments were
performed by means of a modified hemodiafiltration technique. Treat-
ment A was performed using fixed dialysate conductivity; treatment B
made use of the dialysate conductivity derived from a conductivity kinetic
model, in order to obtain an end-dialysis ultrafiltrate conductivity at each
dialysis session that was equal to the mean value determined in the same
patient during the four-week run-in period. Thus, during treatment B, the
expected end-dialysis ultrafiltrate conductivity value of each patient
should have been constant. The study was carried out according to a
multicenter cross-over design of 16 weeks with two treatments (A or B),
two sequences (1 5 ABB and 2 5 BAA), a run-in period of four weeks
(period 1, treatment A), and three consecutive experimental periods of
four weeks each. Analysis of variance for a cross-over design was used for
the statistical analysis. Forty-nine hemodialysis patients prone to intradia-
lytic hypotension (. 25% of sessions) were enrolled from 16 participating
centers, and randomly assigned to either sequence 1 (26 patients) or
sequence 2 (23 patients). Six patients dropped out and four were protocol
violators, which left 39 patients selected for statistical analysis. There was
no difference in the average dialysate conductivity, predialysis and end-
dialysis plasma water ultrafiltrate conductivity or body weight between
treatment A and treatment B. Thus, the observed mean sodium balance
was not different and, as expected, only the intra-patient variability of
end-dialysis ultrafiltrate conductivity (index of sodium balance variability)
was reduced (21%). During treatment A, systolic blood pressure de-
creased by 23 mm Hg (95% confidence intervals 21 to 24 mm Hg) at the
end of dialysis with respect to the pre-dialysis values. Treatment B reduced
this intradialytic decrease (P 5 0.001) with a maximum effect at the third
hour of dialysis (4.4 mm Hg, 95% confidence intervals 1.9 to 6.9 mm Hg,
23% less than during treatment A, P 0.0005) without any period or
carry-over effect (P 5 0.53 and 0.08, respectively). There was no treatment
effect on intradialytic diastolic blood pressure (P 5 0.291). In conclusion,
intradialytic cardiovascular stability was significantly improved by match-
ing the interdialytic sodium load with intradialytic sodium removal using
on-line conductivity ultrafiltrate kinetic modeling as an alternative to
sodium kinetic modeling. Although highly significant, this effect was
clinically not very large. By applying this conductivity kinetic model to
patients with a more variable sodium intake from one session to another,
a greater benefit can be expected.
Despite technological advances in dialysis equipment and mo-
dalities [1, 2], cardiovascular instability during hemodialytic treat-
ment remains an important clinical problem for many reasons: the
progressive aging of the dialytic population, the increased inci-
dence of cardiovascular risk factors, and the tendency to shorten
dialysis treatment time by increasing blood flow, dialyzer surfaces
and ultrafiltration rates.
The importance of adequate sodium removal during hemodi-
alysis sessions has been known for a long time and, over recent
years, sodium dialysate concentrations have been progressively
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increased [3]. Although effective in reducing intradialytic morbid-
ity, such a systematic use of high sodium dialysate is not without
disadvantages, particularly as sodium balance is checked infre-
quently. The problem is to reduce intradialytic hypotension and
the other effects of sodium depletion, while simultaneously pre-
venting overhydration and its possible side effects, such as hyper-
tension and pulmonary edema [4].
Hemofiltration (HF) and hemodiafiltration (HDF) have been
reported to improve cardiovascular stability, possibly because
their effects on peripheral resistances are different from those of
hemodialysis (HD). However, the lower hypotension rates re-
ported for HF and HDF are usually considered to be due to the
fact that sodium removal is less than in HD. This conclusion is
often erroneous since, as has already been pointed out [5, 6],
neither the Donnan effect nor the sieving coefficient are taken
into consideration, and this means that HF and HDF may have
the same potential side effects as those mentioned above.
By using flame photometry, Gotch et al [7] developed a single
pool sodium kinetic model that could be applied to HD but not to
HDF. In fact, when using filtration techniques, sodium removal is
derived not only from the sodium concentrations in the dialysate,
but also from those in the reinfusion fluids. Di Filippo et al [8]
have recently published the results obtained using a single-pool
sodium kinetic model in HD according to Gotch et al [7].
However, unlike the latter authors, they measured sodium levels
by means of direct potentiometry (instead of flame photometry)
because of its greater precision, and were thus able to make a
more accurate calculation of sodium balance. Moreover, using a
modified hemodiafiltration technique, the so-called paired filtra-
tion dialysis, which physically separates convection and diffusion
by means of a double-chamber filter (consisting of a hemofilter
and hemodialyzer) and on-line monitoring of ultrafiltrate conduc-
tivity, a conductivity kinetic model [9] has been developed as an
alternative to the sodium kinetic model (on the basis of the
correlation between the conductivity and sodium concentrations
of each saline solution). The application of this model has been
proven to be a reliable and inexpensive method that makes it
possible to match intradialytic water-sodium removal with inter-
dialytic load at each session, without the need for blood sampling.
Whether this conductivity kinetic model improves cardiovascular
stability needs to be tested in clinical practice, especially in
patients whose sodium intake is highly variable and intradialytic
cardiovascular stability is poor. Therefore, the aim of this multi-
center, prospective, controlled randomized trial was to test
whether cardiovascular stability in hemodialysis patients prone to
dialysis hypotension could be improved by using the model under
conditions in which reinfusate sodium concentrations and the
patients’ dry body wt were left to the usual policy of the attending
physician and maintained constant during the study follow-up.
Only dialysate conductivity (and thus dialysate sodium concentra-
tion) was modified according to the protocol during the experi-
mental treatment in order to obtain an end-dialysis ultrafiltrate
sodium concentration (as estimated by conductivity) that was
equal to the mean value determined in the same patient during
the run-in period. In this way, sodium removal should exactly
match the interdialytic sodium load at each dialysis, thus possibly
reducing the negative clinical effects of too much or too little
sodium removal, that are related to variability in sodium intake
from one session to another.
METHODS
Patients
Uremic patients on stable HD treatment were recruited from
16 participating Centers and the patients who fulfilled the entry
criteria were selected for the study.
Inclusion criteria
Patients, aged more than 18 years, who had been on chronic
thrice-weekly HD for at least six months, and who had been
affected by symptomatic hypotension during three or more dia-
lytic sessions in the last month before entry, were admitted to the
study.
Exclusion criteria
Patients on unstable antihypertensive or erythropoietin ther-
apy, and those with insulin-treated diabetes mellitus or who had
been in unstable clinical condition in the previous six months were
excluded from the study.
Study protocol
The study was carried out according to a multicenter cross-over
design of 16 weeks with two treatments (A or B), two sequences
(sequence 1 5 ABB and sequence 2 5 BAA), a run-in period of
four weeks (period 1, treatment A) and three consecutive exper-
imental periods of four weeks (periods 2, 3 and 4; Fig. 1). The
patients were centrally randomized to one of the two sequences
according to a balanced block randomization list. A cross-over
experimental design was chosen because the expected large
between-patient variability in arterial blood pressure suggested
that it would be more efficient than a classical parallel group study
[10–13]. A 12-month recruitment period was estimated.
Dialysis technique
All of the dialysis sessions were performed using paired filtra-
tion dialysis, a modified hemodiafiltration technique that com-
bines hemofiltration and hemodialysis throughout the treatment
(Fig. 2) [14]. Paired filtration dialysis (PFD) was performed using
a double-chamber filter that splits convective and diffusive fluxes.
The filter consists of a hemofilter (high flux polysulfone 0.5 m2)
and a hemodialyzer (Hemophan® 1.36 m2). The ultrafiltrate from
Fig. 1. Study protocol. Treatment A consisted of a constant dialysate
conductivity, and treatment B used the modeled dialysate conductivity.
Locatelli et al: On-line conductivity kinetic modeling 1053
the hemofilter is completely separated from the dialysate and is
thus available for the continuous monitoring of plasma conduc-
tivity. The reinfusate was infused after hemofiltration. Bicarbon-
ate was used as a buffer in the dialysate. All of the dialysis sessions
were performed using a standard dialysis machine modified for
this technique (Multimat System Plus; Bellco, Mirandola, Italy).
The PFD was performed at constant values of Qb, Qd and total
ultrafiltration rate. Total ultrafiltration rate was constant (3
liters/hr, 85% from the hemofilter and 15% from the hemodia-
lyzer), and net ultrafiltration was equal to total ultrafiltrate minus
the reinfusate. Throughout the 16 weeks of the study, the type of
reinfusate used for each individual patient was always the same.
Only the dialysate sodium concentration (as estimated by conduc-
tivity) was changed in accordance with the study protocol. For
each patient, the prescribed end-dialysis body wt, dialysis time,
blood and dialysate flow rates, as well as the dose of oral sodium
bicarbonate and/or sodium polystyrene sulphonate therapy had to
remain constant.
Treatment definitions
Treatment A. Paired filtration dialysis was performed with a
constant dialysate conductivity equal to that used during dialysis
treatment before the run-in period of the study.
Treatment B. Paired filtration dialysis was performed using a
calculated dialysate conductivity value derived from the conduc-
tivity kinetic model, in order to obtain an end-dialysis ultrafiltrate
conductivity value (as an index of the end-dialysis sodium plasma
water concentration) that was equal to the mean value deter-
mined during the four-week run-in period (Fig. 1). During this
treatment, the patient’s sodium pool at the end of each dialysis
session should therefore have been constant. The ultrafiltrate
conductivity value was routinely provided by the dialysis machine
throughout the session; the value observed five minutes after the
start of dialysis (in order to avoid interference from the filter
rinsing saline solution), was entered in the PC kinetic conductivity
model (Fig. 2). The output from the model provided the value of
dialysate conductivity necessary to achieve the pre-determined
end-dialysis ultrafiltrate conductivity (the mean value observed
during the run-in period). The conductivity kinetic model was
installed in a PC that was not connected with the dialysis machine,
and so the dialysate conductivity value to use during treatment
was manually keyed into the dialysis machine. There was no
servomechanism or feedback control in the model.
Clinical and laboratory measurements
Body weight was recorded at the start and end of each dialysis
session. Heart rate, and systolic and diastolic blood pressure levels
were measured at the start of the dialysis session after the patient
had been lying in the dialysis bed for at least five minutes, after
each subsequent hour, and at the end of the dialysis session before
blood restitution. Body and dialysate temperatures were recorded
at the start and at the end of each session; the dialysate temper-
ature was kept at 37°C throughout the treatment. Intradialytic
symptoms and hypotension were coded and recorded at the end of
each dialysis session: symptoms such as nausea, vomit, cramps,
shivers and headache were recorded as dichotomous variables;
hypotension was considered asymptomatic if systolic blood pres-
sure decreased during dialysis by 30 mm Hg without any clinical
evidence of hypotension, or symptomatic if it associated with
symptoms and/or the administration of i.v. saline. The type and
amount of infused saline solutions were recorded.
Ultrafiltrate conductivity was recorded five minutes after the
start and five minutes before the end of each dialysis session and
dialysate conductivity was recorded five minutes before the end of
each session.
Fig. 2. Diagram showing the modified
hemodiafiltration technique (paired filtration
dialysis, PFD) and the independent PC
conductivity kinetic model. The plasma
ultrafiltrate conductivity value displayed by the
machine was entered in the personal computer
(PC) conductivity kinetic model. The model
output (dialysate conductivity value) was keyed
into the machine. The PC conductivity kinetic
model was used only during treatment B.
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Conductivity kinetic model
The conductivity kinetic model used during treatment B (de-
scribed in detail in reference [9]) calculated the dialysate conduc-
tivity value required to obtain the predetermined end-dialysis
ultrafiltrate conductivity value. The input data were the pretreat-
ment ultrafiltrate conductivity value, the predetermined end-
treatment ultrafiltrate conductivity value, the pretreatment body
wt, the net ultrafiltration, the treatment time, the reinfusate
conductivity value, blood, dialysate and reinfusate flow rates, the
percentage of total ultrafiltration from the hemofilter, and the
ionic diffusive dialysance. Only one type of dialyzer and one type
of reinfusate were used for each patient. Under these conditions,
a constant intradialytic value of ionic diffusive dialysance was
used, which was calculated using a formula that incorporated the
overall mass transfer coefficient for urea (KoA) (equal to 434
ml/min for this dialyzer; see also [9]) and the blood water flow rate
equal to 85% of blood flow. Ionic diffusive dialysance could
therefore change from one session to another if there was a
change in the blood flow rate.
Sodium balance calculation
Sodium balance was calculated from the estimated predialysis
and end-dialysis body water volume and the estimated sodium
plasma water concentration derived from the relation between
ultrafiltrate conductivity and plasma sodium. The estimated end-
dialysis body water volume was considered to be equal to 58% of
end-dialysis body wt. The estimated predialysis body water volume
was considered to be equal to the end-dialysis body water volume
1 D body wt.
Differences in end-dialysis ultrafiltrate conductivity
The differences between the observed and predetermined
end-dialysis ultrafiltrate conductivity values were calculated for
each dialytic session during both treatments. This made it possible
to calculate the different variability in end-dialysis ultrafiltrate
conductivity of the two treatments.
Sample size calculation
The sample size was calculated by considering the difference in
the reduction in intradialytic blood pressure between treatment A
and B as the main response variable of the study. The calculated
sample size of 47 patients was based on the following parameters:
a significance level (that is, an a error) of 0.05; a b error of 0.2; a
power (1-b) of 0.8; an intradialytic reduction in systolic blood
pressure that was 10 mm Hg (SD 20 mm Hg) lower during
treatment B than during treatment A; a two-tailed paired t-test for
both a and b errors; and a drop-out rate of 10%.
Statistical analysis
The descriptive analysis was based on the cross tabulation of the
categorical variables (as symptoms and hypotension frequency)
and the percentile distributions, mean, SD and 95% confidence
intervals of the continuous variables (as systolic and diastolic
blood pressure values, ultrafiltrate and dialysate conductivities
and body wt). The main statistical analysis was carried out
according to the model of the analysis of variance for a cross-over
design with two sequences, two treatments and three periods
using unique sums of squares and treatment A as a reference. The
assumption of normality of the error term required by this model
was tested using the analysis of residuals. The logistic regression
for a cross-over design was used to test the effect of the experi-
mental treatment on the categorical variables. A probability value
of less than 0.05 was considered to be statistically significant. The
statistical analyses were made using SPSS for Windows, Release
6.0.1.
Informed consent and ethical surveillance
Before starting the study, the patients were informed about the
aims, the expected benefits to them and/or others, the risks and
inconveniences involved, as well as of their right to refuse to
participate or to withdraw from the study at any time without
sanction. Their oral informed consent was obtained. The study




Between September 1994 and February 1996, 49 HD patients
from 16 participating centers satisfied the entry criteria, and were
randomized to either sequence 1 (ABB; N 5 26 patients) or
sequence 2 (BAA; N 5 23 patients). Six patients (clinical reasons
3, technical reasons 2, death 1) dropped out and four were
protocol violators. Thus, the analysis was based on 39 hemodial-
ysis patients (80%, 19 males and 20 females, 19 treated with
sequence 1 and 20 with sequence 2), who had been on a thrice
weekly HD schedule for 6.0 6 4.5 years. Baseline patient and
dialysis characteristics of these 39 patients are reported in Table 1.
Intradialytic blood pressure profile
The effect of treatment B on intradialytic cardiovascular insta-
bility was investigated using the intradialytic systolic and diastolic
blood pressure profile. The mean predialytic systolic blood pres-
sure values during treatment A and B (143.9 mm Hg and 143.8
mm Hg, respectively) decreased by respectively 22.7 mm Hg and
19.2 mm Hg at the end of dialysis (Table 2). More interestingly,
treatment B had a significant effect on the systolic blood pressure
profile, with a lower intradialytic reduction in comparison with
treatment A (F test 4.5, P 5 0.001) without any period or
carry-over effect (P 5 0.53 and P 5 0.08, respectively). The
treatment effect was maximal at the third hour (4.4 mm Hg, 23%
less than during treatment A, P 5 0.0005, 95% confidence
Table 1. Baseline characteristics of the 39 analyzed patients
Variable Mean SD
Age years 66.1 12.4
Time on dialysis years 6.0 4.5
Predialysis body weight kg 67.3 13.3
Postdialysis body weight kg 64.8 12.9
Systolic blood pressure mm Hg 142 21
Diastolic blood pressure mm Hg 80 11
Dialysis duration minutes 219 24
Total ultrafiltration rate from hemofilter % 85 9
Reinfusion rate liter/hr 2.5 0.4
Net ultrafiltration rate liter/hr 0.8 0.2
Qb ml/min 309 27
Qd ml/min 500 4
Predialysis ultrafiltrate conductivity mS/cm 14.24 0.25
Postdialysis ultrafiltrate conductivity mS/cm 14.14 0.23
Dialysate conductivity mS/cm 14.14 0.23
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intervals 1.9 to 6.9 mm Hg). There was a strong patient effect (F
test 210, P 5 0.000), which means that there was a large degree of
between-patient variability in systolic blood pressure values. As
expected, the time of dialysis also had a strong effect on systolic
blood pressure values (F test 397, P 5 0.000); this effect was
evident as early as the first hour, and was maximal at the end of
dialysis. The beneficial effect of treatment B on the intradialytic
reduction in systolic blood pressure is shown in Figure 3.
The mean predialytic diastolic blood pressure during treat-
ments A and B (79.0 mm Hg and 80.6 mm Hg, respectively)
decreased by respectively 8.3 and 8.5 mm Hg at the end of dialysis;
there was therefore no treatment effect on the intradialytic
diastolic blood pressure profile (F test 1.24, P 5 0.291) but, as
expected, there was a large patient (F test 74, P 5 0.000) and
dialytic (F test 92, P 5 0.000) effect.
Frequency of dialytic symptoms and hypotension
Frequency and percent of the sessions with symptoms and
hypotension by sequence groups are shown in Table 3. There was
a trend towards a reduction in the intradialytic frequency of
symptoms between treatment A and treatment B (9% vs. 6%, a
reduction of 33%, P 5 0.051) as well as in asymptomatic or
symptomatic hypotension (42% vs. 35%, a reduction of 17%, P 5
0.083). Both data are consistent with a trend towards better
cardiovascular stability with treatment B, although at different
non-significant P values. The effect of treatment B on hypotension
was evident only in sequence 1 with a reduction of hypotension
frequency of 25% (from 40% to 30% of sessions; Table 3). The
pattern of the effect of treatment B was the same when asymp-
tomatic and symptomatic hypotension were considered separately
(data not shown).
Sodium balance
There was no difference between treatment A and treatment B
in terms of mean predialysis and end-dialysis body wt (predialysis
67.6 kg vs. 67.5 kg; end 65.1 kg vs. 65.0 kg, respectively; Fig. 4), or
in the conductivity values of the ultrafiltrate (predialysis 14.24
mS/cm vs. 14.23 mS/cm; end-dialysis 14.10 mS/cm vs. 14.11
mS/cm, respectively) and dialysate (14.11 mS/cm vs. 14.11 mS/cm,
respectively; Fig. 5). The average estimated sodium balance (21
mEq/session vs. 23 mEq/session, respectively) was therefore
similar between the two treatments (Fig. 6).
Differences in end-dialysis ultrafiltrate conductivity
The median SD of the difference between the observed and
predetermined end-dialysis ultrafiltrate conductivity was 0.092 on
treatment A and 0.068 mS/cm on treatment B (a reduction of
26%) in sequence 1, and 0.069 on treatment A and 0.060 mS/cm
on treatment B (a reduction of 13%) in sequence 2, the overall
reduction being 21% (from 0.081 to 0.064). The effect of treat-
ment B in reducing the variability of end-dialysis ultrafiltrate
conductivity is shown in Figure 7. This effect was most evident in
sequence 1 where the baseline SD of the difference between the
observed and predetermined end-dialysis ultrafiltrate conductivity
was higher than in sequence 2 (0.092 vs. 0.069).
Other variables
There were no differences in body and dialysate temperatures
between treatment A and treatment B (data not shown). The type
and sodium concentration of reinfusate (chosen by the attending
nephrologists) was kept constant in each patient during the study
(data not shown). There was also no change during the study in
the reinfusion rate, total and net ultrafiltration rate, percentage of
Fig. 3. Effect of experimental treatment B on the intradialytic percentage
reduction in systolic blood pressure. There was a significant smaller
reduction in intradialytic systolic blood pressure values, with a maximum
effect at the third hour of dialysis (23% less than during treatment A, P 5
0.0005).














mm Hg p valueb
Start 143.9 143.8
1 133.5 210.4c 133.9 29.9c 20.5 0.657
2 129.8 214.1c 132.1 211.7c 22.4 0.049
3 124.7 219.2c 129.0 214.8c 24.4 0.001
End 121.2 222.7c 124.6 219.2c 23.5 0.005
a There was a significant effect of experimental treatment B, with a lower intradialytic reduction in systolic blood pressure in comparison with the
conventional treatment A (global F test 4.45, P 5 0.001).
b P values of the effect of experimental treatment B in comparison with conventional treatment A at different hours of dialysis. A smaller intradialytic
reduction in systolic blood pressure was evident from the 2nd hour of dialysis and was maximal at the 3rd hour.
c The effect of the time of dialysis vs. start dialysis (P 5 0.000) was evident as early as the 1st hour, and was maximal at the end of dialysis.
Locatelli et al: On-line conductivity kinetic modeling1056
total ultrafiltration from the hemofilter, dialysis time, filter type,
filter surface area, or blood and dialysate flow rates (data not
shown).
DISCUSSION
Cardiovascular instability occurs in more than 30% of dialytic
sessions and thus greatly affects the morbidity, quality of life and
mortality of uremic patients undergoing chronic hemodialysis
programs. The adequacy of intradialytic sodium and water re-
moval plays a pivotal role in preventing both intradialytic hypo-
tension (or other adverse effects of sodium depletion) and
overhydration (leading to hypertension, left ventricular hypertro-
phy or even acute pulmonary edema). In clinically stable patients,
the amount of water and sodium accumulated during the inter-
dialytic period has to be removed at each dialysis session to obtain
a zero sodium balance. Since the basic sodium and water load
varies from one uremic patient to another and (a crucial point for
this study) also in the same patient, its removal must be individ-
ualized by adjusting total ultrafiltration so that it is equal to the
interdialytic weight gain and the end-dialysis plasma sodium
concentration as a “constant value” [15]. In this way, the risk of
intradialytic hypotension and interdialytic hypertension and pul-
monary edema should be reduced. The sodium kinetic model
makes it possible to calculate the dialysate sodium concentration
needed to achieve a constant end-dialysis plasma water sodium
concentration. It also makes it possible to obtain a dialytic sodium
removal that is almost equivalent to the interdialytic load [15].
However, as it requires the determination of at least the plasma
water sodium at the start of each session, its routine use is rather
impractical. As is true for saline solutions, plasma water conduc-
tivity is linearly dependent on sodium concentration, thus making
it possible to use conductivity instead of sodium concentration
values. The conductivity method is inexpensive and avoids the
need for blood and dialysate sampling. Furthermore, the results
are immediately available at no additional cost [16–20].
Plasma conductivity (as an index of plasma water sodium
Fig. 4. Predialysis (M) and postdialysis (u)
body weights. There was no difference in
predialysis and end-dialysis body weights
between the conventional treatment A and
experimental treatment B.
Table 3. Intradialytic frequency of symptoms and hypotensiona by sequence and treatment groupsb
Sequence
1 (ABB) 2 (BAA) All
Treatment Treatment Treatment
A B A B A B % Reduction P c
Symptoms
Frequency 18 27 44 14 62 41
% 8 6 10 6 9 6 (33) 0.051
Sessions 225 442 453 236 678 678
Hypotension
Frequency 89 134 197 103 286 237
% 40 30 43 44 42 35 (17) 0.083
Sessions 225 443 453 236 678 679
a Symptomatic and asymptomatic hypotension considered together.
b The numbers in brackets are the % reductions in these variables on treatment B in comparison with treatment A. There was a trend in the overall
reduction of intradialytic symptoms (33%, P 5 0.051) and hypotension (17%, P 5 0.083).
c P value from logistic regression analysis
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concentration) and ionic dialysance (as an index of sodium
dialysance) are two key variables for the clinical implementation
of sodium kinetic model in dialysis patients. The modified hemo-
diafiltration technique we used (PFD) makes it easy to measure
plasma conductivity from pure ultrafiltrate (unmixed with dialy-
sate) and calculate ionic dialysance. A zero water-sodium balance
can be obtained by adjusting intradialytic ultrafiltration to a level
that is equal to interdialytic weight gain and the end-dialytic
plasma ultrafiltrate sodium concentration (as estimated by con-
ductivity) at a “constant” value. This on-line conductivity kinetic
model could also be used in standard hemodialysis if there were a
device for collecting a small amount of ultrafiltrate or for mea-
suring inlet and outlet dialysate conductivity at two different inlet
dialysate conductivity values [16–20].
The results of this study show that the application of the
conductivity kinetic model improves cardiovascular stability in
selected patients prone to dialysis hypotension by significantly
reducing the intradialytic drop in systolic blood pressure. More-
over, the frequency of dialysis symptoms and hypotension consis-
tently showed a trend towards better cardiovascular stability with
experimental treatment B. We would like to underline that the
improvement in cardiovascular stability was obtained by simply
matching intradialytic sodium and water removal with the inter-
dialytic sodium and water load at each dialysis session, thus
reducing the variability in sodium balance related to day-to-day
variations in sodium intake. The drop in intradialytic systolic, but
not diastolic, blood pressure values was significantly reduced. The
statistical cross-over design made it possible to take the high
degree of between-patient variability in blood pressure values into
account. It is important to underline that these results were
obtained without modifying the concentrations of sodium reinfu-
sate, the temperature of the dialysate or body, or the dry body wt
chosen by the attending nephrologists for their patients. Only
dialysate conductivity (and thus dialysate sodium concentration)
Fig. 5. Predialysis and postdialysis ultrafiltrate
and dialysate conductivities. There was no
difference in dialysate and predialysis (MX ) and
end-dialysis (F) plasma ultrafiltrate conductivity
between treatments. Symbol (X) is dialysate
conductivity.
Fig. 6. Interdialytic load (M), dialytic removal
(u) and sodium balance (f). There was no
difference in the estimated average sodium
balance between treatments.
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was modified according to the protocol to obtain an ultrafiltrate
conductivity at the end of each session that was equal to the mean
value determined in the same patient during the run-in period. In
accordance with the study design, this value was not different
between the two treatments. Only the variability of end-dialysis
ultrafiltrate conductivity (Fig. 7) was lower during experimental
treatment B than during standard treatment A. In line with the
protocol rationale, this should be the key factor related to the
better cardiovascular stability during the experimental treatment
B.
The fact that, although highly significant, the effect on cardio-
vascular stability was clinically not very large can possibly be
ascribed to the fact that, despite the selection criteria, the patients
did not have a highly variable sodium intake from one session to
another. We can estimate that 95% of this patient population had
a baseline mismatch in sodium balance from one session to
another of 61 mEq/session or less (less than half a liter of isotonic
saline solution). Thus, the potential benefit of applying the
conductivity kinetic model was theoretically reduced because the
model is likely to be more suitable for patients whose sodium
intake is highly variable. The mismatch in sodium balance on
conventional treatment was therefore not very large and this
could have reduced the possibility of improving cardiovascular
stability on the experimental treatment. In line with this pathoge-
netic mechanism, a greater improvement in cardiovascular stabil-
ity on experimental treatment B was observed in sequence 1
(Table 3), where the baseline variability of end-dialysis ultrafil-
trate plasma sodium was higher than in sequence 2 and where the
effect of experimental treatment B on the reduction in the
variability of end-dialysis ultrafiltrate plasma sodium (as esti-
mated by conductivity) was more evident (Fig. 7).
In conclusion, by applying this conductivity kinetic model to
patients prone to intradialytic hypotension, we observed a signif-
icantly lower reduction in intradialytic systolic blood pressure
values, and a trend toward a reduction in the intradialytic
frequency of symptoms and hypotension, without modifying the
dialysate and reinfusate sodium concentration values, or dry body
wt, chosen by the attending nephrologists for their patients.
Although highly significant, the clinical effect on systolic blood
pressure was not very large. However, all of the results are
consistent with the hypothesis of the study. By applying this
conductivity kinetic model to patients whose sodium intake from
one session to another is more variable than that of the patients in
this study, one would expect a larger benefit on intradialytic
patient cardiovascular stability. Whether a further improvement
in cardiovascular stability could be obtained by modulating the
sodium profile during dialysis [21] and/or by better defining
patient dry body wt was beyond the scope of this trial and needs
to be tested in other prospective controlled randomized studies.
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